Ascelia Pharma Q3: Cash and progress - Redeye

After the recent rights issue, Ascelia has SEK 95.7m, and the company has a runway to end 2025. The Full Study Report for Orviglance is completed, and the next stage is to engage in pre-submission meetings with the FDA on the way to a formal submission by mid-2025. Orviglance continues to feature at conferences, which is important as Ascelia is pursuing a partner strategy for the future launch of Orviglance.

Länk till analysen i sin helhet: https://www.redeye.se/research/1053117/ascelia-pharma-q3-cash-and-progress?utm_source=finwire&utm_medium=RSS